Phase I study of gemcitabine (GEM) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Kawabata, S [1 ]
Oka, M [1 ]
Fukuda, M [1 ]
Kinoshita, A [1 ]
Fukuda, M [1 ]
Nagashima, S [1 ]
Nakamura, Y [1 ]
Nakano, H [1 ]
Soda, H [1 ]
Kohno, S [1 ]
机构：
[1] Nagasaki Univ, Nagasaki 852, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7291
引用
收藏
页码：688S / 688S
页数：1
相关论文
共 50 条
  • [31] Phase I/II study of exisulind and gemcitabine in patients with recurrent advanced non-small cell lung cancer (NSCLC).
    Hoang, T
    Kim, K
    Merchant, J
    Traynor, AM
    Ahuja, HG
    Masters, GA
    McGovern, JD
    Oettel, KR
    Sanchez, FA
    Schiller, JH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 642S - 642S
  • [32] Carboplatin plus gemcitabine followed by weekly paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC): A phase II study
    Tjan-Heijnen, V
    Timmer-Bonte, J
    van der Drift, M
    van Leeuwen, F
    de Boo, T
    Wagenaar, M
    van Die, L
    Bussink, J
    LUNG CANCER, 2005, 49 : S272 - S272
  • [33] A multicenter phase II study of docetaxel (D) and carboplatin (CBDCA) combination in advanced non-small cell lung cancer (NSCLC). A preliminary analysis.
    Giannakakis, T
    Kakolyris, S
    Papadouris, S
    Mavroudis, D
    Kalbakis, K
    Souglakos, J
    Agelaki, S
    Passam, F
    Mixaki, J
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2000, 11 : 120 - 120
  • [34] A phase II and pharmacogenomic study of Irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC).
    Pillot, GA
    Hennenfent, K
    Read, W
    Marsh, S
    McLeod, HL
    Gao, F
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 648S - 648S
  • [35] A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer
    Tognoni, A
    Pensa, F
    Vaira, F
    Vigani, A
    Canessa, P
    Sinaccio, G
    Pronzato, P
    JOURNAL OF CHEMOTHERAPY, 2002, 14 (03) : 296 - 300
  • [36] Gemcitabine (GEM) and carboplatin (CARB) in elderly patients with advanced non-small cell lung cancer (NSCLC): Subset analysis of a randomized phase II trial.
    Masters, GA
    Nickolov, A
    Hahn, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 679S - 679S
  • [37] Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC): A phase II study
    Orlandi-Jorquera, L
    Orlandi, F
    Galaz, P
    Gamargo, C
    Salman, P
    Yanez, M
    ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
  • [38] Gemcitabine and cisplatin for advanced non-small cell lung cancer (NSCLC)
    Casal, J
    Grande, C
    Caeiro, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1083 - 1083
  • [39] Phase I study of low-dose cisplatin (CDDP) and gemcitabine (GEM) chemotherapy for elderly patients with advanced non-small cell lung cancer (NSCLC)
    Buffoni, L.
    Dongiovanni, D.
    Barone, C.
    Fissore, C.
    Larovere, E.
    Grillo, R.
    Salvadori, A.
    Birocco, N.
    Ciuffreda, L.
    Bertetto, O.
    Schena, M.
    ANNALS OF ONCOLOGY, 2006, 17 : XI21 - XI22
  • [40] Phase I and pharmacokinetic study of the combination of vinflunine (VFL) and gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts)
    Bennouna, J
    Lemarie, E
    Grossi, F
    Carballido, F
    Sennelart, H
    Leger, F
    Douillard, J
    LUNG CANCER, 2005, 49 : S236 - S236
12345